Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Dose-Response Relationship, Drug.
  1. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother. 2012 Mar; 56(3):1223-8.
    View in: PubMed
    Score: 0.046
  2. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother. 2008 Jun; 52(6):1924-8.
    View in: PubMed
    Score: 0.036
  3. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother. 2006 Dec; 58(6):1185-92.
    View in: PubMed
    Score: 0.032
  4. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother. 2005 Jul; 49(7):2642-7.
    View in: PubMed
    Score: 0.029
  5. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005 May; 25(5):409-13.
    View in: PubMed
    Score: 0.029
  6. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Int J Antimicrob Agents. 2004 Aug; 24(2):173-7.
    View in: PubMed
    Score: 0.028
  7. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004 Jul; 54(1):178-86.
    View in: PubMed
    Score: 0.027
  8. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother. 2003 Oct; 52(4):616-22.
    View in: PubMed
    Score: 0.026
  9. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses. J Antimicrob Chemother. 2001 Dec; 48(6):821-6.
    View in: PubMed
    Score: 0.023
  10. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn Microbiol Infect Dis. 2001 Aug; 40(4):167-71.
    View in: PubMed
    Score: 0.022
  11. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J Antimicrob Chemother. 1999 Apr; 43(4):483-90.
    View in: PubMed
    Score: 0.019
  12. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob Agents Chemother. 1998 Nov; 42(11):2841-7.
    View in: PubMed
    Score: 0.019
  13. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. Antimicrob Agents Chemother. 1987 Nov; 31(11):1782-6.
    View in: PubMed
    Score: 0.009
  14. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model. Int J Antimicrob Agents. 2007 Feb; 29(2):165-9.
    View in: PubMed
    Score: 0.008
  15. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Jul; 20(1):44-9.
    View in: PubMed
    Score: 0.006
  16. An artificial capillary in vitro kinetic model of antibiotic bactericidal activity. J Infect Dis. 1981 Dec; 144(6):583-7.
    View in: PubMed
    Score: 0.006
  17. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis. 1981 Oct; 144(4):365-71.
    View in: PubMed
    Score: 0.006
  18. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents. 2000 Dec; 16(4):407-14.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.